2D illustrations and photos
Metagenomi Technologies (MGX), which develops precision gene therapies, has filed for a planned $100 million initial public offering.
The biotech company didn't disclose terms in its SEC filing, but indicated it wanted to raise $100 million, a figure that seems likely a placeholder and subject to change.
Metagenomi hopes to list its shares on the Nasdaq under the symbol MGX. The deal's underwriters include JP Morgan, Jefferies, TD Cowen, Wells Fargo Securities, BMO Capital Markets and Chardan.
Based in Emeryville, California, Metagenomi is focused on developing curative therapies for genetic diseases such as hemophilia A and TTR using its proprietary genome editing toolbox. The company's drug candidates are still in the preclinical stage.
Comments are closed.